个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Zhou, Q.[1] * ; Zhang, H. -L.[2] ; Jiang, L. -Y.[3] ; Shi, Y. -K.[4] ; Chen, Y.[5,20] ; Yu, J. -M.[6] ; Zhou, C. -C.[7] ; He, Y.[8,9] ; Hu, Y. -P.[10] ; Liang, Z. -A.[11] ; Pan, Y. -Y.[12] ; Zhuo, W. -L.[13] ; Song, Y.[14] ; Wu, G.[15] ; Chen, G. -Y.[16] ; Lu, Y.[17] ; Zhang, C. -Y.[18] ; Zhang, C. -Y.[18] ; Zhang, Y. -P.[19] ; Chen, Y.[5,20] ; Lu, S.[3] ; Wu, Y. -L.[1] ;
单位： [1]Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China [2]Fourth Mil Med Univ, Tangdu Hosp, Xian, Peoples R China [3]Shanghai Chest Hosp, Shanghai, Peoples R China [4]Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China [5]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China [6]Shandong Univ, Shandong Canc Hosp, Shandong, Peoples R China [7]Shanghai Pulm Hosp, Shanghai, Peoples R China [8]Third Mil Med Univ, Daping Hosp, Chongqing, Peoples R China [9]Third Mil Med Univ, Inst Surg Res, Chongqing, Peoples R China [10]Hubei Canc Hosp, Wuhan, Peoples R China [11]West China Sch Med, Chengdu, Peoples R China [12]Anhui Med Univ, Hosp 1, Hefei, Peoples R China [13]Inst Resp Dis PLA, Chongqing, Peoples R China [14]Gen Hosp Eastern Theater Command Chinese Peoples, Nanjing, Peoples R China [15]Huazhong Univ Sci & Technol, Coll Med, Union Hosp, Wuhan, Peoples R China [16]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [17]West China Hosp, Chengdu, Peoples R China [18]Inner Mongolia Autonomous Region Peoples Hosp, Hohhot, Peoples R China [19]Zhejiang Canc Hosp, Hangzhou, Peoples R China [20]Jilin Canc Hosp, Changchun, Peoples R China
出处：
ISSN：

关键词： Non-small-cell lung cancer Osimertinib EGFR T790M-positive

基金：
AstraZeneca
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2020]版：
Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者单位： [1]Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou Q.,Zhang H. -L.,Jiang L. -Y.,et al.ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)[J].JOURNAL OF THORACIC ONCOLOGY.2022,17(9):S429-S430.
APA：
Zhou, Q.,Zhang, H. -L.,Jiang, L. -Y.,Shi, Y. -K.,Chen, Y....&Wu, Y. -L..(2022).ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC).JOURNAL OF THORACIC ONCOLOGY,17,(9)
MLA：
Zhou, Q.,et al."ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)".JOURNAL OF THORACIC ONCOLOGY 17..9(2022):S429-S430

相关文献

[1]AURA17 study of osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC): Updated phase II results including overall survival (OS) [2]Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study [3]Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms [4]Final results of APOLLO study: Overall survival (OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [5]Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial [6]Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) [7]A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer [8]Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3/SOCS3 and KEAP1/NRF2 pathways in non-small cell lung cancer [9]Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations [10]Progress of non-small-cell lung cancer with ROS1 rearrangement

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）